Meropenem

Generic Name
Meropenem
Brand Names
Vabomere
Drug Type
Small Molecule
Chemical Formula
C17H25N3O5S
CAS Number
96036-03-2
Unique Ingredient Identifier
YOP6PX0BAO
Background

Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.

In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and Vaborbactam and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.

Indication

For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.

Associated Conditions
Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
Associated Therapies
-

RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.

First Posted Date
2014-06-26
Last Posted Date
2017-11-27
Lead Sponsor
The University of Queensland
Target Recruit Count
391
Registration Number
NCT02176122
Locations
🇮🇹

Catholic University Rome, Rome, Italy

🇹🇷

İstanbul Medipol Üniversitesi Medipol Mega Hastaneler Kompleksi (Medipol Mega Hospitals Complex), Istanbul, Turkey

🇦🇺

Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

and more 28 locations

Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations

First Posted Date
2014-01-28
Last Posted Date
2020-05-04
Lead Sponsor
University of Edinburgh
Target Recruit Count
90
Registration Number
NCT02047773
Locations
🇬🇧

Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis

First Posted Date
2013-11-25
Last Posted Date
2013-11-25
Lead Sponsor
Erzhen Chen
Target Recruit Count
60
Registration Number
NCT01992198
Locations
🇨🇳

Depatrment of EICU,Ruijin Hospital, Shanghai, Shanghai, China

Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem

First Posted Date
2012-11-22
Last Posted Date
2017-04-12
Lead Sponsor
Mical Paul
Target Recruit Count
406
Registration Number
NCT01732250
Locations
🇮🇱

Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

🇮🇱

Rambam Health Care Center, Haifa, Israel

🇬🇷

Laikon Hosptial, Athens, Greece

and more 4 locations

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

First Posted Date
2012-11-14
Last Posted Date
2017-09-06
Lead Sponsor
Pfizer
Target Recruit Count
486
Registration Number
NCT01726023
Locations
🇻🇳

Research Site, Hochiminh, Vietnam

Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-03-14
Last Posted Date
2015-02-16
Lead Sponsor
PENTA Foundation
Target Recruit Count
51
Registration Number
NCT01554124
Locations
🇬🇧

HEATH, Paul, London, Cranmer Terrace, United Kingdom

Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis

First Posted Date
2012-03-12
Last Posted Date
2015-02-16
Lead Sponsor
PENTA Foundation
Target Recruit Count
272
Registration Number
NCT01551394
Locations
🇮🇹

Ursula TRAFOJER, Padova, Italy

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

First Posted Date
2011-12-26
Last Posted Date
2017-09-06
Lead Sponsor
Pfizer
Target Recruit Count
493
Registration Number
NCT01499290
Locations
🇺🇦

Research Site, Zaporizhzhya, Ukraine

© Copyright 2024. All Rights Reserved by MedPath